E-cadherin EC2-EC5 Subdomain Targeting for Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in selectively targeting cancer cells without harming normal healthy tissues, as many chemotherapeutics are non-selectively cytotoxic, leading to systemic drug toxicity and poor patient outcomes.
Innovation Solution
Development of antibodies and compositions that specifically target the EC2-EC5 subdomains of E-cadherin, avoiding the EC1 subdomain, to selectively kill cancer cells by inducing apoptosis or inhibiting cell survival signals, while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective chemotherapeutics are used to kill cancer cells, then cancer cell death is achieved, but normal healthy cells are also damaged causing systemic toxicity
Solution Approach 1:
The invention segments the E-cadherin extracellular domain into five distinct subdomains (EC1-EC5) and identifies that antibodies targeting EC2-EC5 subdomains specifically kill cancer cells while sparing normal cells. This segmentation allows selective targeting of cancer cells based on their unique E-cadherin shedding characteristics, resolving the contradiction between cancer cell killing efficacy and systemic toxicity.
Solution Approach 2:
The invention applies local quality by directing therapeutic action specifically to cancer cells through antibodies that bind to the EC2-EC5 subdomains of shed E-cadherin, which are uniquely present on cancer cell surfaces. Normal cells do not exhibit this shedding pattern, so they remain unaffected. This localized targeting achieves reliable cancer cell death while avoiding harm to healthy tissues.
2Stability of the object's composition
If antibodies targeting EC1 subdomain are used, then cell-cell adhesion can be maintained, but cancer cell selectivity is lost
Solution Approach 1:
The invention extracts the therapeutic target from the full-length E-cadherin protein by focusing specifically on the soluble extracellular domain fragments (EC2-EC5) that are shed from cancer cells. By taking out this specific fragment as the target, the invention achieves cancer cell selectivity while leaving the membrane-anchored EC1 subdomain intact to maintain normal cell-cell adhesion functions.
Solution Approach 2:
The invention uses antibodies as intermediaries that specifically recognize and bind to the EC2-EC5 subdomains of shed E-cadherin on cancer cells. These antibodies serve as mediators that translate the presence of shed E-cadherin fragments into selective cancer cell death signals, while not interfering with the EC1-mediated cell-cell adhesion in normal tissues.
3Reliability
If full-length E-cadherin is targeted, then all epithelial cells are affected, but cancer cell selectivity cannot be achieved
Solution Approach 1:
The invention exploits the dynamic difference between normal and cancer cells regarding E-cadherin shedding. Normal cells maintain stable full-length E-cadherin at the membrane, while cancer cells dynamically shed the extracellular domain to produce soluble EC2-EC5 fragments. By targeting this dynamic shedding product rather than the static full-length protein, the invention achieves tumor selectivity while maintaining broad epithelial cell coverage in normal tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively induces cell death in epithelial-derived tumor cells without affecting non-epithelial cells, offering a potential solution for treating cancers like breast, lung, and skin cancers with reduced toxicity and improved patient outcomes.
Implementation Method 1
antibodies and compositions that specifically target the EC2-EC5 subdomains of E-cadherin, avoiding the EC1 subdomain, to selectively kill cancer cells by inducing apoptosis
Data Source
Figure 1A~1B
Figure 2A~2C
AI summary
The present invention is based, in part, on our discovery that targeting epitopes within one or more of the EC2-EC5 subdomains of E-cadherin results in the death of epithelial -derived tumor cells but not in the death of normal, healthy epithelial cells or non-epithelial cells including endothelial cells and fibroblasts. Accordingly, the compositions of the invention include polypeptides having an amino acid sequence of one or more of the EC2-EC5 subdomains of E-cadherin and biologically active variants thereof; expression vectors and cells for expressing such polypeptides; and agents (e.g., antibodies) that target the EC2-EC5 subdomains. The methods of the invention include methods of identifying and producing polypeptides having an amino acid sequence of one or more of the EC2-EC5 subdomains of E-cadherin or a biologically active variant thereof; methods of generating agents, such as antibodies, that target these polypeptides; and methods of administering such agents or eliciting their production in vivo to treat epithelial cancers or reduce the risk of their occurrence or recurrence.